These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28648859)

  • 1. Ceftriaxone versus ceftriaxone plus a macrolide for community-acquired pneumonia in hospitalized patients with HIV/AIDS: a randomized controlled trial.
    Figueiredo-Mello C; Naucler P; Negra MD; Levin AS
    Clin Microbiol Infect; 2018 Feb; 24(2):146-151. PubMed ID: 28648859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
    Lode H; File TM; Mandell L; Ball P; Pypstra R; Thomas M;
    Clin Ther; 2002 Nov; 24(11):1915-36. PubMed ID: 12501883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of β-Lactam Monotherapy vs Macrolide Combination Therapy for Children Hospitalized With Pneumonia.
    Williams DJ; Edwards KM; Self WH; Zhu Y; Arnold SR; McCullers JA; Ampofo K; Pavia AT; Anderson EJ; Hicks LA; Bramley AM; Jain S; Grijalva CG
    JAMA Pediatr; 2017 Dec; 171(12):1184-1191. PubMed ID: 29084336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
    File TM; Eckburg PB; Talbot GH; Llorens L; Friedland HD
    Int J Antimicrob Agents; 2017 Aug; 50(2):247-251. PubMed ID: 28599867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
    Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
    JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial.
    Ceccato A; Cilloniz C; Ranzani OT; Menendez R; Agusti C; Gabarrus A; Ferrer M; Sibila O; Niederman MS; Torres A
    PLoS One; 2017; 12(6):e0178022. PubMed ID: 28617807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Respiratory fluoroquinolone monotherapy vs. β-lactam plus macrolide combination therapy for hospitalized adults with community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials.
    Choi SH; Cesar A; Snow TAC; Saleem N; Arulkumaran N; Singer M
    Int J Antimicrob Agents; 2023 Sep; 62(3):106905. PubMed ID: 37385561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of empiric β-lactam monotherapy and β-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia.
    Ambroggio L; Taylor JA; Tabb LP; Newschaffer CJ; Evans AA; Shah SS
    J Pediatr; 2012 Dec; 161(6):1097-103. PubMed ID: 22901738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of macrolide therapy on mortality of HIV-infected patients with community-acquired pneumonia in a tertiary teaching hospital.
    Mello CF; Negra MD
    Braz J Infect Dis; 2011; 15(3):262-7. PubMed ID: 21670928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis.
    Asadi L; Sligl WI; Eurich DT; Colmers IN; Tjosvold L; Marrie TJ; Majumdar SR
    Clin Infect Dis; 2012 Aug; 55(3):371-80. PubMed ID: 22511553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gatifloxacin in the treatment of community-acquired pneumonias: a comparative trial of ceftriaxone, with or without macrolides, in hospitalized adult patients with mild to moderately severe pneumonia.
    Mendonça JS; Yamaguti A; Corrêa JC; Badaró R
    Braz J Infect Dis; 2004 Feb; 8(1):90-100. PubMed ID: 15286880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of ceftriaxone plus macrolide and ampicillin/sulbactam plus macrolide in treatment for patients with community-acquired pneumonia without risk factors for aspiration: an open-label, quasi-randomized, controlled trial.
    Hamao N; Ito I; Konishi S; Tanabe N; Shirata M; Oi I; Tsukino M; Matsumoto H; Yasutomo Y; Kadowaki S; Hirai T
    BMC Pulm Med; 2020 Jun; 20(1):160. PubMed ID: 32503515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Efficacy of Beta-Lactams and Macrolides in the Treatment of Pediatric Pneumonia: A Systematic Review.
    Al Saeedy D; Gillani SW; Al-Salloum J; Moosvi A; Eissa M; Gulam SM
    Curr Pediatr Rev; 2020; 16(4):307-313. PubMed ID: 32895041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
    Lodise TP; Kwa A; Cosler L; Gupta R; Smith RP
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3977-82. PubMed ID: 17709460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia.
    Dresser LD; Niederman MS; Paladino JA
    Chest; 2001 May; 119(5):1439-48. PubMed ID: 11348951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia.
    Arnold FW; Lopardo G; Wiemken TL; Kelley R; Peyrani P; Mattingly WA; Feldman C; Gnoni M; Maurici R; Ramirez JA;
    Respir Med; 2018 Jul; 140():115-121. PubMed ID: 29957272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis.
    Sligl WI; Asadi L; Eurich DT; Tjosvold L; Marrie TJ; Majumdar SR
    Crit Care Med; 2014 Feb; 42(2):420-32. PubMed ID: 24158175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization.
    Peyrani P; Wiemken TL; Metersky ML; Arnold FW; Mattingly WA; Feldman C; Cavallazzi R; Fernandez-Botran R; Bordon J; Ramirez JA
    Infect Dis (Lond); 2018 Jan; 50(1):13-20. PubMed ID: 28699429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients.
    Izadi M; Dadsetan B; Najafi Z; Jafari S; Mazaheri E; Dadras O; Heidari H; SeyedAlinaghi S; Voltarelli F
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):228-239. PubMed ID: 30360748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia.
    Zervos M; Mandell LA; Vrooman PS; Andrews CP; McIvor A; Abdulla RH; de Caprariis PJ; Knirsch CA; Amsden GW; Niederman MS; Lode H
    Treat Respir Med; 2004; 3(5):329-36. PubMed ID: 15606222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.